Myricetin activates glucagon-like peptide 1 (GLP-1), increases adropin levels, and reduces hyperglycemia
Secondary endpoints, assessed in time-to-first-event analyses and tested in hierarchical order, included death from cardiovascular causes, a composite heart failure endpoint (death from cardiovascular causes or hospitalization or an urgent medical visit for heart failure), and death from any cause
Instead of forcing the brain to ignore hunger, they replicate a hormone your body already produces, glucagon-like peptide-1, and they do it at concentrations high enough to create dramatic shifts in appetite, digestion, and metabolic function
At 48 weeks, 93% of participants on the 12 mg dose achieved normal liver fat levels (below 5%), with a mean relative reduction of 86% in hepatic fat content